PeptidePedia The community reference

Talk:Arcuate nucleus

Discussion page·2 threads·no archives

This article is within the scope of the pharmacology working group.

This is the discussion page for the article Arcuate nucleus. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Inverse agonism at MC4RResolved

AgRP is usually described as an antagonist. Calling it an inverse agonist is more accurate but will look like an error to readers who learned it the other way. Worth the half-sentence of explanation the article gives. MelanocortinMil (talk) 10:15, 28 February 2026 (UTC)

Agreed — the explanation is what makes the distinction useful rather than pedantic, since constitutive activity is why the receptor matters clinically. ✓ Done ArcuateArt (talk) 13:50, 28 February 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

How much animal work should be cited as though it were human?

Several statements here rest on rodent studies. The article says so in one place. It should probably say so in each. PrimarySrcPatia (talk) 11:40, 14 April 2026 (UTC)

I have added "in animal models" to the POMC-activation sentence and kept the general statement that human contributions are inferred rather than measured. Repeating it in every sentence would be unreadable. ArcuateArt (talk) 15:25, 14 April 2026 (UTC)

That is a reasonable balance — one explicit statement of provenance plus a marker on the strongest claim. PrimarySrcPatia (talk) 09:00, 15 April 2026 (UTC)

This page was last edited on 15 April 2026, by PrimarySrcPatia. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).